Lung Cancer Trial, Recruiting (NCT07339254)

Lung Cancer Trial, Recruiting NCT07339254 Sponsor: University of Southern California Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07339254 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older
People who have a confirmed diagnosis of non-small cell lung cancer (a type of lung cancer), confirmed through laboratory testing of tissue or cell samples
People who are currently receiving one of the following immunotherapy medicines: Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, or Pembrolizumab, and have already completed at least one full cycle of that treatment
People who have previously received other cancer treatments such as chemotherapy, radiation therapy, targeted therapy, or immunotherapy at any point in the past
People who are able to understand and sign a consent form, or who have a designated substitute decision-maker who is able to give consent on their behalf

Who may not be able to join:

People who are unable to give consent for themselves and do not have a substitute decision-maker available to consent on their behalf
People who have not yet finished their first cycle of immunotherapy treatment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07339254

Sponsor: University of Southern California

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT07339254

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older
People who have a confirmed diagnosis of non-small cell lung cancer (a type of lung cancer), confirmed through laboratory testing of tissue or cell samples
People who are currently receiving one of the following immunotherapy medicines: Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, or Pembrolizumab, and have already completed at least one full cycle of that treatment
People who have previously received other cancer treatments such as chemotherapy, radiation therapy, targeted therapy, or immunotherapy at any point in the past
People who are able to understand and sign a consent form, or who have a designated substitute decision-maker who is able to give consent on their behalf

Who may not be able to join:

People who are unable to give consent for themselves and do not have a substitute decision-maker available to consent on their behalf
People who have not yet finished their first cycle of immunotherapy treatment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Southern California

Registry

ClinicalTrials.gov

Start date

12 March 2026

Est. completion

12 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy; Patient interest in home SC ICI administration vs. IV ICI administration at the infusion center

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov